X-linked lymphoproliferative disease

X-linked lymphoproliferative disease
Synonyms	Duncan's disease
Pronounce	N/A
Specialty	N/A
Symptoms	Infectious mononucleosis, hypogammaglobulinemia, lymphoma, hemophagocytic lymphohistiocytosis
Complications	Liver failure, bone marrow failure, cancer
Onset	Childhood
Duration	Chronic
Types	N/A
Causes	Genetic mutation in the SH2D1A or XIAP genes
Risks	Family history of the disease
Diagnosis	Genetic testing, blood test, immunological assay
Differential diagnosis	Common variable immunodeficiency, autoimmune lymphoproliferative syndrome
Prevention	N/A
Treatment	Hematopoietic stem cell transplantation, immunoglobulin therapy, antiviral therapy
Medication	Rituximab, corticosteroids
Prognosis	Variable, often poor without treatment
Frequency	Rare
Deaths	High mortality rate without treatment

X-linked lymphoproliferative disease (XLP), also known as Duncan's disease or Purtilo syndrome, is a rare genetic disorder characterized by an inappropriate immune response to the Epstein-Barr virus (EBV). This condition primarily affects males and can lead to severe immunological complications.

Causes

XLP is caused by mutations in specific genes located on the X chromosome:

• XLP1: Resulting from mutations in the SH2D1A gene, which encodes the SLAM-associated protein (SAP). Deficiencies in SAP impair the function of T and natural killer (NK) cells, leading to uncontrolled immune responses upon EBV infection.
• XLP2: Caused by mutations in the *XIAP* gene, leading to defects in apoptosis regulation and immune system dysfunction.

Symptoms

Individuals with XLP may exhibit:

• Fulminant Infectious Mononucleosis (FIM): An exaggerated response to EBV infection, leading to severe illness.
• Hemophagocytic Lymphohistiocytosis (HLH): A life-threatening condition characterized by excessive immune activation and tissue damage.
• Dysgammaglobulinemia: Abnormal levels of immunoglobulins, resulting in increased susceptibility to infections.
• Lymphomas: Increased risk of developing cancers of the lymphatic system.

Diagnosis

Diagnostic approaches include:

• Genetic testing: Identifying mutations in the SH2D1A or XIAP genes.
• Immunological assessments: Evaluating immune cell function and immunoglobulin levels.
• Family History analysis: Considering the X-linked inheritance pattern to assess risk in male relatives.

Treatment

Management strategies encompass:

• Hematopoietic stem cell transplantation (HSCT): The only curative treatment, replacing defective immune cells with healthy donor cells.
• Immunoglobulin replacement therapy: Administering immunoglobulins to prevent infections.
• Targeted therapies: Utilizing medications to modulate immune responses and control symptoms.

Prognosis

Without treatment, XLP often leads to severe complications and reduced life expectancy. Early diagnosis and appropriate interventions, such as HSCT, can significantly improve outcomes.

References

• MedlinePlus: X-linked lymphoproliferative disease
• GeneReviews: X-linked lymphoproliferative disease